Treatment against honeybee varroosis based on highly effective application of oxalic acid through sublimation

Projektinformationen

BEEOXAL

ID Finanzhilfevereinbarung: 781067

DOI 10.3030/781067

Abgeschlossenes Projekt

EK-Unterschriftsdatum 14 Juli 2017

Startdatum 1 August 2017

Enddatum 30 November 2017

Finanziert unter

• SOCIETAL CHALLENGES - Climate action, Environment, Resource Efficiency and Raw Materials

Gesamtkosten € 71 429,00

EU-Beitrag € 50 000,00

Koordiniert durch

SAGAVET SOLUCIONES S.L.
Spain

Ziel

Varroosis is the most serious honeybee disease worldwide, causing €197 million loss yearly in the eight main European beekeeping countries, and severe population decline of this main pollination agent, with strong impact on agriculture and wildlife biodiversity. Negative effects are of such extent that the EU provides specific funding (€33.1 M, 2014-16), to support beekeepers applying compulsory annual anti-varroosis treatments, but current medicaments cannot effectively control varroosis because none, either synthetic of organic, guarantee all the features required for optimal pest control: 1) High efficacy; 2) natural and safe for humans, honeybees and environment; 3) no resistance development; 4) Easy-to-use. BEEOXAL outmatches existing solutions by combining these four features. It consists of a treatment kit with (1) easy-to-use mono-dose pellets and (2) a specifically developed device that burns (sublimates) the tablet so it is spread like a cloud inside the hive. BEEOXAL results from the research and vast field experience of Sagavet Soluciones SL, a Spanish SME delivering animal health solutions. Based on a component already present in honey, oxalic acid, BEEOXAL has an efficacy of 96.8%, a large therapeutic margin thanks to improved spot-on formulation and dosage. Unlike synthetic products, BEEOXAL’s organic nature ensures no residue. The ready-for-use mono-dose pellets do not require mixing or handling, and the burner device to directly sublimate the tablet inside each hive allows a homogeneous distribution of the medicament in 30 seconds (x6 times faster than current treatments). This is crucial since it allows beekeepers to work safely and to avoid under/over doses (secure), maximising overall effectiveness. Backed by its international network (Cenavisa, Byopic), Soluciones Apícolas forecasts €6.8 million cumulative revenue for 2020-2022, and payback of 1 year, while generating 12 new jobs.

Wissenschaftliches Gebiet

• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs
• natural sciences › biological sciences › zoology › entomology › apidology
• social sciences › economics and business › business and management › business models
• natural sciences › biological sciences › ecology › ecosystems
• agricultural sciences › animal and dairy science › apiculture

Programm/Programme

• H2020-EU.3.5. - SOCIETAL CHALLENGES - Climate action, Environment, Resource Efficiency and Raw Materials Main Programme
• H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument

Thema/Themen

• SMEInst-11-2016-2017 - Boosting the potential of small businesses in the areas of climate action, environment, resource efficiency and raw materials

Aufforderung zur Vorschlagseinreichung

H2020-SMEInst-2016-2017

Andere Projekte für diesen Aufruf anzeigen

Unterauftrag

H2020-SMEINST-1-2016-2017

Finanzierungsplan

SME-1 - SME instrument phase 1

Koordinator

SAGAVET SOLUCIONES S.L.

• Netto-EU-Beitrag: € 50 000,00
• Adresse: C/ BALANCO I BOTER 22, ATICO, PLANTA 2A ; 08302 MATARO BARCELONA ; Spanien
• KMU Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen). Ja:
  Region
  Este › Cataluña › Barcelona
• Region: Este › Cataluña › Barcelona
• Aktivitätstyp: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Gesamtkosten: € 71 429,00